These results substantiate the clinical value of imaging, which may be further enhanced by molecular imaging with [18F]FDG or emerging radiopharmaceuticals targeting tumor-associated antigens like carbonic anhydrase IX (CAIX) to identify patients in need of urgent systemic or local therapy. This evidence concerns the gene CA9 and neoplasm.